Form 4: Myriad Genetics Chief Technology Officer Reports Stock Transactions

Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reports acquisition of restricted stock units and disposal of shares to cover tax obligations.

Summary

• On March 14, 2024, Kevin Richard Haas, the Chief Technology Officer of Myriad Genetics, acquired 35,178 shares of common stock through time-based restricted stock units.
• These restricted stock units were granted under the company's 2017 Employee, Director and Consultant Equity Incentive Plan and vest in three equal annual installments starting one year from the grant date.
• On March 15, 2024, Haas disposed of 3,306 shares at a price of $21.16 to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Haas directly owns 136,672 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine stock transactions related to executive compensation. There are no indications of significant positive or negative developments.

Positives

• The acquisition of restricted stock units demonstrates the company's commitment to incentivizing its executives.
• The vesting schedule of the restricted stock units encourages long-term commitment from the executive.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's holdings.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates changes in the holdings of a key executive at Myriad Genetics.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates